Urteste Unveils Plans for Innovative Clinical Trials
Urteste S.A., a leader in cancer detection technology, is gearing up to begin clinical trials in Europe for its unique pancreatic cancer test. This significant step forward in medical diagnostics is part of their ongoing project, Panuri. The trials are expected to start in the third quarter of the year, marking a major milestone in the journey of developing this groundbreaking diagnostic tool.
Collaboration and Preparation for Trials
To ensure the success of their clinical trials, Urteste plans to collaborate closely with a Contract Research Organization (CRO). This selection process will be initiated shortly, in preparation for the studies to be held in Poland and other EU countries. The trials will involve approximately 550 patients, which will provide crucial data for evaluating the effectiveness of the test.
Trial Design and Objectives
The trials aim to establish the diagnostic capabilities of the Panuri test, which utilizes innovative urine sample analysis. Urteste’s CEO, Grzegorz Stefa?ski, emphasized the trials' potential to yield quicker and more cost-effective results compared to similar studies in other regions, particularly the United States.
Future of Cancer Detection
While emphasizing its commitment to enhancing diagnostic methods for pancreatic cancer, Urteste is also preparing for concurrent trials in the United States. This includes a pivotal meeting with the FDA, to finalize trial parameters and patient requirements.
Internal Validation and Broader Impact
By mid-2025, Urteste anticipates completing the internal validation of the Panuri test. This self-validation will prepare them further for the upcoming clinical trials in both Europe and the U.S. The technology developed by Urteste will not only focus on pancreatic cancer but is part of a comprehensive array of diagnostic tests for various other cancers, including breast, brain, and colorectal cancer.
Looking Toward Commercialization
With 12 prototype diagnostic tests already developed, Urteste strives to simplify cancer detection and increase accessibility for patients. Their innovative approach measures enzyme activity through urine samples, providing a non-invasive method to detect cancer early, which is vital in saving lives.
About Urteste and Its Commitment
Founded with the mission of early cancer detection through technological advancement, Urteste works with experienced managers and scientists specializing in medical technology and enzyme chemistry. Their dedication to improving cancer diagnostics aligns with their motto, "Early cancer detection saves lives." This philosophy drives every aspect of their research and development efforts.
Contact Urteste for More Information
For individuals seeking additional details about Urteste and its innovative projects, contact information is provided below:
Urteste S.A.
Grzegorz Stefa?ski, CEO urteste@urteste.eu
Frequently Asked Questions
What is Urteste's primary focus?
Urteste focuses on developing innovative diagnostics technology for early cancer detection, particularly through urine analysis.
When will the clinical trials for the Panuri test commence?
The clinical trials for the Panuri test are planned to start in the third quarter of the year.
What types of cancers does Urteste aim to detect?
Urteste is developing tests for various cancers, including pancreatic, breast, brain, and many others associated with high mortality rates.
How can I get more information about Urteste?
Contact Urteste directly through the provided email for the latest updates and further information.
Why is early cancer detection important?
Early detection significantly improves treatment outcomes and survival rates, making innovative diagnostic methods crucial in the fight against cancer.
